{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:52:23Z","timestamp":1791640343466,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000324","name":"Gatsby Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neurol.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:05:32Z","timestamp":1743386732000},"page":"438-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent progress and challenges in gene therapy for pharmacoresistant focal epilepsy"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6696-3545","authenticated-orcid":false,"given":"D.M.","family":"Kullmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2025.02.008_bib0300","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.02.008_bib0305","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3171\/2018.3.JNS171722","article-title":"An estimation of global volume of surgically treatable epilepsy based on a systematic review and meta-analysis of epilepsy","volume":"130","author":"Vaughan","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.neurol.2025.02.008_bib0310","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/WNL.0000000000002253","article-title":"Recognizing and preventing epilepsy-related mortality: a call for action","volume":"86","author":"Devinsky","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.02.008_bib0315","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/epi.17560","article-title":"Magnetic resonance-guided laser interstitial thermal therapy for drug-resistant epilepsy: a systematic review and individual participant data meta-analysis","volume":"64","author":"Chen","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.02.008_bib0320","doi-asserted-by":"crossref","first-page":"101342","DOI":"10.1016\/j.omtm.2024.101342","article-title":"A novel AAV9-dual microRNA-vector targeting GRIK2 in the hippocampus as a treatment for mesial temporal lobe epilepsy","volume":"32","author":"Baudouin","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurol.2025.02.008_bib0325","unstructured":"uniQure. Phase I\/IIa Clinical Trial of AMT-260 | Programs & Pipeline. uniQure n.d. https:\/\/www.uniqure.com\/programs-pipeline\/phase-i-iia-clinical-trial-of-amt-260 [accessed January 24, 2025]."},{"key":"10.1016\/j.neurol.2025.02.008_bib0330","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-323-90820-7.00016-1","article-title":"Epilepsies","volume":"203","author":"McTague","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.neurol.2025.02.008_bib0335","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/brain\/awad336","article-title":"Extracellular glutamate and GABA transients at the transition from interictal spiking to seizures","volume":"147","author":"Shimoda","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.02.008_bib0340","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1126\/science.abq6656","article-title":"On-demand cell-autonomous gene therapy for brain circuit disorders","volume":"378","author":"Qiu","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neurol.2025.02.008_bib0345","doi-asserted-by":"crossref","first-page":"161ra152","DOI":"10.1126\/scitranslmed.3004190","article-title":"Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy","volume":"4","author":"Wykes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0350","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/ncomms2376","article-title":"On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy","volume":"4","author":"Krook-Magnuson","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2025.02.008_bib0355","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nn.3269","article-title":"Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury","volume":"16","author":"Paz","year":"2013","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurol.2025.02.008_bib0360","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1073\/pnas.0901915106","article-title":"Optogenetic control of epileptiform activity","volume":"106","author":"T\u00f8nnesen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2025.02.008_bib0365","doi-asserted-by":"crossref","first-page":"106234","DOI":"10.1016\/j.nbd.2023.106234","article-title":"Optogenetics for controlling seizure circuits for translational approaches","volume":"184","author":"Ledri","year":"2023","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2025.02.008_bib0370","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fncel.2018.00293","article-title":"Chemogenetic recruitment of specific interneurons suppresses seizure activity","volume":"12","author":"C\u01celin","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurol.2025.02.008_bib0375","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13311-021-01160-0","article-title":"Chemogenetic seizure control with clozapine and the novel ligand JHU37160 outperforms the effects of levetiracetam in the intrahippocampal kainic acid mouse model","volume":"19","author":"Desloovere","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2025.02.008_bib0380","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/epi.16368","article-title":"Long-term chemogenetic suppression of spontaneous seizures in a mouse model for temporal lobe epilepsy","volume":"60","author":"Desloovere","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.02.008_bib0385","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/epi.16840","article-title":"Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy","volume":"62","author":"Goossens","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.02.008_bib0390","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41467-024-44853-8","article-title":"Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice","volume":"15","author":"Nguyen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2025.02.008_bib0395","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1172\/JCI95731","article-title":"Chemogenetic silencing of hippocampal neurons suppresses epileptic neural circuits","volume":"129","author":"Zhou","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2025.02.008_bib0400","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.expneurol.2016.07.003","article-title":"Chemogenetic silencing of the midline and intralaminar thalamus blocks amygdala-kindled seizures","volume":"283","author":"Wicker","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2025.02.008_bib0405","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1038\/ncomms4847","article-title":"Chemical-genetic attenuation of focal neocortical seizures","volume":"5","author":"K\u00e4tzel","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2025.02.008_bib0410","doi-asserted-by":"crossref","first-page":"107751","DOI":"10.1016\/j.neuropharm.2019.107751","article-title":"Optogenetic and chemogenetic therapies for epilepsy","volume":"168","author":"Walker","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2025.02.008_bib0415","doi-asserted-by":"crossref","first-page":"eaaw1567","DOI":"10.1126\/sciadv.aaw1567","article-title":"Olanzapine: a potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics","volume":"5","author":"Weston","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.neurol.2025.02.008_bib0420","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41591-018-0103-x","article-title":"Biochemical autoregulatory gene therapy for focal epilepsy","volume":"24","author":"Lieb","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0425","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3390\/jcm13144224","article-title":"Optogenetics and targeted gene therapy for retinal diseases: unravelling the fundamentals, applications, and future perspectives","volume":"13","author":"Kulbay","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0430","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2019.09.004","article-title":"Disease modification by combinatorial single vector gene therapy: a preclinical translational study in epilepsy","volume":"15","author":"Melin","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurol.2025.02.008_bib0435","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymthe.2006.04.004","article-title":"Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo","volume":"14","author":"McCown","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0440","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/hum.2022.037","article-title":"Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet syndrome mouse model and is well tolerated in nonhuman primates","volume":"33","author":"Tanenhaus","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0445","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/brain\/awaa045","article-title":"In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy","volume":"143","author":"Colasante","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.02.008_bib0450","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0070-23.2023","article-title":"CaMKII\u03b1 promoter-controlled circuit manipulations target both pyramidal cells and inhibitory interneurons in cortical networks","volume":"10","author":"Veres","year":"2023","journal-title":"eNeuro"},{"key":"10.1016\/j.neurol.2025.02.008_bib0455","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/dneu.22459","article-title":"Application of viral vectors to the study of neural connectivities and neural circuits in the marmoset brain","volume":"77","author":"Watakabe","year":"2017","journal-title":"Devel Neurobio"},{"key":"10.1016\/j.neurol.2025.02.008_bib0460","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.gt.3301905","article-title":"Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area","volume":"10","author":"K\u00fcgler","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0465","first-page":"52","article-title":"Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1","volume":"26","author":"Chandler","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurol.2025.02.008_bib0470","first-page":"1","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0475","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.02.008_bib0480","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurol.2025.02.008_bib0485","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2023.12.006","article-title":"Focused ultrasound gene delivery for the treatment of neurological disorders","volume":"30","author":"Kofoed","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0490","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurol.2025.02.008_bib0495","doi-asserted-by":"crossref","first-page":"eadn5603","DOI":"10.1126\/scitranslmed.adn5603","article-title":"Inteerneuron-specific dual-AAV SCN1A gene replacement corrects epileptic phenotypes in mouse models of Dravet syndrome","volume":"17","author":"Mich","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0500","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1523\/JNEUROSCI.1143-18.2019","article-title":"Epilepsy gene therapy using an engineered potassium channel","volume":"39","author":"Snowball","year":"2019","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2025.02.008_bib0505","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/gt.2008.186","article-title":"Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors","volume":"16","author":"Rahim","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0510","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.neurol.2025.02.008_bib0515","doi-asserted-by":"crossref","first-page":"102280","DOI":"10.1016\/j.omtn.2024.102280","article-title":"Emerging trends in virus and virus-like particle gene therapy delivery to the brain","volume":"35","author":"Mandalawatta","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2025.02.008_bib0520","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1021\/acschembio.4c00247","article-title":"Miniature CRISPR-Cas12 systems: mechanisms, engineering, and genome editing applications","volume":"19","author":"Tang","year":"2024","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.neurol.2025.02.008_bib0525","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtn.2018.10.016","article-title":"A single H1 promoter can drive both guide RNA and endonuclease expression in the CRISPR-Cas9 system","volume":"14","author":"Gao","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2025.02.008_bib0530","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymthe.2019.08.018","article-title":"dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice","volume":"28","author":"Colasante","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0535","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/brain\/awad387","article-title":"Anti-seizure gene therapy for focal cortical dysplasia","volume":"147","author":"Almacellas Barbanoj","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.02.008_bib0540","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3171\/2020.4.JNS20701","article-title":"Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders","volume":"134","author":"Lonser","year":"2020","journal-title":"J Neurosurg"},{"key":"10.1016\/j.neurol.2025.02.008_bib0545","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3171\/JNS-07\/09\/0560","article-title":"Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles","volume":"107","author":"Szerlip","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1016\/j.neurol.2025.02.008_bib0550","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMoa1703784","article-title":"Histopathological findings in brain tissue obtained during epilepsy surgery","volume":"377","author":"Blumcke","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0555","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nm.3824","article-title":"Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy","volume":"21","author":"Lim","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0560","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2051-5960-2-71","article-title":"Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies","volume":"2","author":"Liu","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurol.2025.02.008_bib0565","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1038\/ncomms11753","article-title":"Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement","volume":"7","author":"Hsieh","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2025.02.008_bib0570","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nm901","article-title":"Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion","volume":"9","author":"Haberman","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0575","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/gt.2010.23","article-title":"Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus","volume":"17","author":"Noe","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2025.02.008_bib0580","doi-asserted-by":"crossref","first-page":"e9963","DOI":"10.15252\/emmm.201809963","article-title":"Dynorphin-based \u201crelease on demand\u201d gene therapy for drug-resistant temporal lobe epilepsy","volume":"11","author":"Agostinho","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurol.2025.02.008_bib0585","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41598-017-17786-0","article-title":"Selective targeting of Scn8a prevents seizure development in a mouse model of mesial temporal lobe epilepsy","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2025.02.008_bib0590","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nbd.2014.01.015","article-title":"Optogenetic inhibition of chemically induced hypersynchronized bursting in mice","volume":"65","author":"Berglind","year":"2014","journal-title":"Neurobiol Dis"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725004837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725004837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:14:38Z","timestamp":1762218878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725004837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0035378725004837"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.02.008","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress and challenges in gene therapy for pharmacoresistant focal epilepsy","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}